MedTrace Logo

Clinical Study of R744 to Peritoneal Dialysis Patients

NCT00433849 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2009-02-02

No results posted yet for this study

Summary

This study will assess the efficacy and safety of subcutaneous or intravenous R744 in renal anemia patients on Peritoneal Dialysis.

Conditions

  • Peritoneal Dialysis Patients

Interventions

DRUG

R744

100μg(i.v./p.o.)/4weeks for 8 weeks, then 25\~400μg(i.v./p.o.)/4weeks for 40 weeks

DRUG

R744

150μg(i.v./p.o.)/4weeks for 8 weeks, then 25\~400μg(i.v./p.o.)/4weeks for 40 weeks

Sponsors & Collaborators

  • Chugai Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Takanori Baba · Clinical Research Department 2

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-10-31
Completion
2008-11-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00433849 on ClinicalTrials.gov